Other Income & Expense
Interest Expense
Alnylam Pharmaceuticals Interest Expense increased by 5.9% to $69.29M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 18.8%, from $58.31M to $69.29M. Over 4 years (FY 2021 to FY 2025), Interest Expense shows an upward trend with a 9.9% CAGR.
Analysis
StatementIncome Statement
SectionOther Income & Expense
First reportedQ1 2016
Last reportedQ1 2026Apr 30, 2026
Metric ID:
interest_expenseHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $33.42M | $40.27M | $36.82M | $42.36M | $42.61M | $41.08M | $29.91M | $28.96M | $30.04M | $30.89M | $31.34M | $35.25M | $33.26M | $34.38M | $38.97M | $58.31M | $40.25M | $44.40M | $65.40M | $69.29M |
| QoQ Change | — | +20.5% | -8.6% | +15.1% | +0.6% | -3.6% | -27.2% | -3.2% | +3.7% | +2.9% | +1.4% | +12.5% | -5.7% | +3.4% | +13.4% | +49.6% | -31.0% | +10.3% | +47.3% | +5.9% |
| YoY Change | — | — | — | — | +27.5% | +2.0% | -18.8% | -31.6% | -29.5% | -24.8% | +4.8% | +21.8% | +10.7% | +11.3% | +24.4% | +65.4% | +21.0% | +29.2% | +67.8% | +18.8% |
Range$28.96M – $69.29M
CAGR+16.6%
Avg YoY Growth+12.5%
Median YoY Growth+15.0%
Current Streak3 quarters growth
Interest Expense at Other Companies
Frequently Asked Questions
- What is Alnylam Pharmaceuticals's interest expense?
- Alnylam Pharmaceuticals (ALNY) reported interest expense of $69.29M in Q1 2026.
- How has Alnylam Pharmaceuticals's interest expense changed year-over-year?
- Alnylam Pharmaceuticals's interest expense increased by 18.8% year-over-year, from $58.31M to $69.29M.
- What is the long-term trend for Alnylam Pharmaceuticals's interest expense?
- Over 4 years (2021 to 2025), Alnylam Pharmaceuticals's interest expense has grown at a 9.9% compound annual growth rate (CAGR), from $143.02M to $208.35M.